Under construction – not a live service
Sign in
Taking people in United StatesNo phase

Following how advanced medullary thyroid cancer develops and progresses over time

Collects information on how advanced medullary thyroid cancer develops and progresses in adults.

Plain-language title generated from the registry record
Registry title: Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management

Key facts

Where
Houston and San Francisco, United StatesSee the 2 sites

Where in United States

  • M D Anderson Cancer CenterHouston, United StatesTaking people
  • University of California San FranciscoSan Francisco, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
M.D. Anderson Cancer Center
Trial code
NCT04216732
Record updated
25 September 2026
Original description
This study utilizes a multi-institutional registry to describe the natural history of medullary thyroid cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) in understanding disease management. The goal of this study is to learn about how medullary thyroid cancer develops and progresses.Read full original descriptionShow less

Utilization of the Natural History of Medullary Thyroid Carcinoma to Inform Advanced Disease Management

This study utilizes a multi-institutional registry to describe the natural history of medullary thyroid cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) in understanding disease management. The goal of this study is to learn about how medullary thyroid cancer develops and progresses.

Inclusion: Aims 1 and 2: A diagnosis of MTC; Aims 1 and 2: A registrant in the Medullary Thyroid Cancer Registry (MTCR). Patients of all disease phases will be eligible for enrollment; Aim 3: A diagnosis of advanced phase (red or gray) MTC as determined by clinical team; Aim 3: A current registrant in the MTCR.

ClinicalTrials.gov NCT04216732